Synergia Life Sciences Pvt. Ltd. has been granted a European patent for the use of vitamin K2 menaquinone-7, branded MenaquinGold, in improvement of blood perfusion, amelioration of hypoxia in venous insufficiency, and in treatment of post thrombotic syndrome (PTS) complications in humans, according to a press release.
MenaquinGold is manufactured through a fermentation technology production process using the Bacillus licheniformis strain of bacteria.
European patent No. EP2178818 covers:
- Use in the improvement of blood perfusion and amelioration of hypoxia in venous insufficiency in humans, when the venous insufficiency is not in varicose veins.
- Use in relief from signs and symptoms of chronic venous insufficiencies in humans, wherein the venous insufficiency manifestations consist of paresthesiae, itching, cramps, and/or heaviness of limbs.
- Use in the treatment of PTS complications in humans, wherein the complications consist of heaviness, cramps, itching, and/or tingling in limbs.
Dr. Dilip Mehta, CEO of Synergia Life Sciences, said in the press release: “Synergia is pleased to receive this patent on Natural vitamin K2 (MK-7), MenaquinGold. MenaquinGold has a contribution in wide range of therapeutics especially in cardiovascular and metabolic health. Due to this increasing acceptance of MenaquinGold as an essential nutrient for human health, it has created a strong recognition globally.”
Dr. Ashok Viadya, Research Director at Kasturba Health Society-Medical Research Centre, who guided the research, added: “The research on vitamin K2 MK-7 highlights the beneficial and versatile role of vitamin K2 MK-7 in relieving fatigue by improving perfusion and increasing oxygenation and energy supply. Vitamin K2 MK-7 improves the venous tone resulting in improvement of venous perfusion and flow, diminishing of venous stasis, chance of inflammation and thrombosis.”